检索结果-南通市图书馆

Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program:A longitudinal study

World Journal of Gastroenterology 2020年第38期26卷 5874-5883页

作者： Arantza Sanvisens Inmaculada Rivas Eva Faure néstor espinach Anna Hernandez-Rubio Xavier Majó Joan Colom Robert Muga Department of Internal Medicine Hospital Universitari Germans Trias i PujolBadalona 08916Spain Mental Health and Addiction Service Badalona Serveis Assistencials-BSABadalona 08911Spain Department of Internal Medicine Hospital Universitari Germans Trias i PujolUniversitat Autònoma de BarcelonaBadalona 08916Spain Program on HIV STIs and Viral Hepatitis-PCAVIHV Public Health Agency of CataloniaGeneralitat de CatalunyaBarcelona 08005Spain

BACKGROUnD Direct-acting antivirals(DAAs)are recommended for the treatment of hepatitis C virus(HCV)infection in patients treated with methadone or *** To assess HCV treatment rates in an Opioid Treatment Program(OTP).METHODS This longitudinal study included 501 patients(81.4%men,median age:45 years;interquartile range:39-50 years)enrolled in an OTP between October 2015 and September *** were followed until September *** on sociodemographics,substance use,HCV infection,human immunodeficiency virus(HIV)infection and laboratory parameters were collected at *** analyzed medical records to evaluate HCV ***-Meier methods and Cox regression models were used to analyze the DAA treatment uptake and to identify treatment *** Prevalence of HCV and HIV infection was 70%and 34%,*** anti-HCV-positive(n=336)patients,47.2%,41.3%,and 31.9%used alcohol,cannabis,and cocaine,***-RnA tests were positive in 233(69.3%)*** patients(8.3%)cleared the infection,and 59/308(19.1%)had received interferon-based treatment regimens before *** 249 patients eligible,111(44.6%)received *** rates significantly increased over time from 7.8/100 person-years(p-y)(95%CI:5.0-12.3)in 2015 to 18.9/100 p-y(95%CI:11.7-30.3)in *** a multivariate analysis,patients with HIV co-infection were twice as likely to receive DAAs(HR=1.94,95%CI:1.21-3.12)than patients with HCV *** drug use was an independent risk factor for not receiving treatment against infection(HR=0.48,95%CI:0.29-0.80).COnCLUSIOn HCV treatment is evolving in patients with HCV-HIV *** drug use while in an OTP might negatively impact the readiness to treat infection.

关键词： Direct-acting antiviral agents Opioid Treatment Program Opioid agonist therapy Hepatitis C virus infection Human immunodeficiency virus infection Drug use

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：